Grail
Grail Launches Galleri Cancer Early Detection Test, Backed by First PATHFINDER Interventional Data
Premium
The company presented its first analyses answering crucial questions about real-world performance and impact on patients' well-being and healthcare utilization.
Illumina Challenges European Commission's Jurisdiction Over Review of Grail Acquisition in EU General Court
Illumina continues to fight against European regulators who want the European Commission to review the deal under untested legal mechanisms.
European Union to Review Illumina's Planned Grail Acquisition Under New Guidance
Illumina reaffirmed its commitment to the $8 billion deal and said it does not believe the European authorities have jurisdiction to review it.
Recent results from the firm's case-control study cohort showed overall sensitivity of about 50 percent but higher performance for a subset of high-mortality cancers.
The US Federal Trade Commission's recent challenge raises the question who Illumina can acquire while remaining a quasi-monopolist for sequencing equipment.